Jay Venkatesan
CIK 1413350 · See Remarks · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.01M
Companies
8
Total Filings
54
Lifetime Open-Market Net
$70.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SER | Director | 232,294 | $2.06 | $478.5K | $1.0K | 5 | 2026-06-22 |
| ELTX | Director | 180,534 | $2.94 | $530.8K | $0 | 6 | 2025-05-20 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 256,759 | $64.97 | $16.68M | -$2.74M | 11 | 2022-07-19 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | See Remarks | 143,952 | $10.00 | $1.44M | -$3.95M | 10 | 2022-05-27 |
| XCUR | Director | 3,123 | $1.66 | $5.2K | $500.0K | 3 | 2020-07-08 |
| IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted | Director | — | — | — | $0 | 3 | 2017-06-05 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | EVP and General Manager | 4,076,723 | — | — | $500.0K | 7 | 2014-12-16 |
| Targanta Therapeutics Corp. (TARG) Delisted | Director | 2,092,987 | — | — | $5.75M | 2 | 2008-06-03 |
Recent Filings · Page 6 of 6
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-05-18 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Exer (X) | −88,000 | -$264.0K | EDGAR |
| 2011-05-12 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Exer (X) | −6,000 | -$12.0K | EDGAR |
| 2008-06-03 | Targanta Therapeutics Corp. (TARG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-10-17 | Targanta Therapeutics Corp. (TARG) Delisted | Mixed | +2,667,987 | $5.75M | EDGAR |
Showing 51–54 of 54
Prev
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.